IBio Analyst Ratings
IBio Analyst Ratings
While ratings are subjective and will change, the latest iBio (IBIO) rating was a downgraded with a price target of $2.50 to $0.17. The current price iBio (IBIO) is trading at is $0.16, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/07/2022 | 7.59% | Cantor Fitzgerald | $2.5 → $0.17 | Downgrades | Overweight → Neutral |
| 11/29/2021 | 849.37% | JMP Securities | → $1.5 | Initiates Coverage On | → Outperform |
| 01/22/2021 | 1798.73% | Cantor Fitzgerald | → $3 | Initiates Coverage On | → Overweight |
| 01/21/2021 | 1798.73% | Cantor Fitzgerald | → $3 | Initiates Coverage On | → Overweight |
| 06/26/2020 | 1640.51% | Alliance Global Partners | → $2.75 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2022 年 7 月 10 日 | 7.59% | 坎託·菲茨傑拉德 | 2.5 美元 → 0.17 美元 | 降級 | 超重 → 中性 |
| 11/29/2021 | 849.37% | JMP 證券 | → 1.5 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 1 月 22 日 | 1798.73% | 坎託·菲茨傑拉德 | → 3 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2021 年 1 月 21 日 | 1798.73% | 坎託·菲茨傑拉德 | → 3 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 06/26/2020 | 1640.51% | 聯盟全球合作伙伴 | → 2.75 美元 | 啓動覆蓋範圍開啓 | → 購買 |
iBio Questions & Answers
iBio 問題與解答
The latest price target for iBio (AMEX: IBIO) was reported by Cantor Fitzgerald on October 7, 2022. The analyst firm set a price target for $0.17 expecting IBIO to rise to within 12 months (a possible 7.59% upside). 2 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2022年10月7日公佈了iBio（美國證券交易所股票代碼：IBIO）的最新目標股價。該分析公司將目標股價定爲0.17美元，預計IBIO將在12個月內升至12個月內（可能上漲7.59％）。去年有2家分析公司公佈了評級。
The latest analyst rating for iBio (AMEX: IBIO) was provided by Cantor Fitzgerald, and iBio downgraded their neutral rating.
坎託·菲茨傑拉德對iBio（美國證券交易所股票代碼：IBIO）的最新分析師評級由坎託·菲茨傑拉德提供，iBio下調了中性評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of iBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for iBio was filed on October 7, 2022 so you should expect the next rating to be made available sometime around October 7, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表、與iBio的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。iBio的最新評級是在2022年10月7日發佈的，因此您應該預計下一個評級將在2023年10月7日左右公佈。
While ratings are subjective and will change, the latest iBio (IBIO) rating was a downgraded with a price target of $2.50 to $0.17. The current price iBio (IBIO) is trading at is $0.16, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的iBio（IBIO）評級已下調，目標股價爲2.50美元，至0.17美元。iBio（IBIO）目前的交易價格爲0.16美元，超出了分析師的預期區間。
